Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KAND 567

Drug Profile

KAND 567

Alternative Names: AZD-8797; KAN-0440567; KAND-567

Latest Information Update: 26 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Kancera
  • Class Analgesics; Anti-inflammatories; Antineoplastics; Cardiovascular therapies; Small molecules
  • Mechanism of Action Chemokine CXCL13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Autoimmune disorders; Cancer; Cancer pain; Myocardial infarction
  • Preclinical Breast cancer; Cardiovascular disorders; Pancreatic cancer
  • Discontinued Multiple myeloma

Most Recent Events

  • 04 Dec 2019 Immunogenicity data from a phase Ib trial in Healthy volunteers released by Kancera
  • 26 Nov 2019 Kancera plans a phase IIa trial for Myocardial infarction (IV) (PO) in the second quarter of 2020
  • 23 Aug 2019 Kancera submits supplemental dosing strategy for the continued implementation of the study to Swedish Medical Products Agency in August 2019 (9273407;9273422)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top